A single but durable stable disease sends the microcap's stock up 730%.
ApexOnco Front Page
Recent articles
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Questions continue to swirl as the unit mulls another oncology makeover.
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.